Sesen Bio, Inc. (SESN) NASDAQ
0.63
+0.0427(+7.29%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Sesen Bio, Inc.
Address
245 First Street
Cambridge, MA 02142
United States of America (the)
Phone
617 444 8550
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
February 06, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Thomas R. Cannell | Pres, Chief Executive Officer & Director | 798,612 | 1962 |
| Glen C. MacDonald | Chief Technology Officer | 512,267 | 1951 |
| Monica Forbes | Chief Financial Officer & Treasurer | 527,405 | 1976 |
| Dennis Kim | Chief Medical Officer | 0 | 1969 |
| David Brooks | Senior Vice President of Clinical Devel. | 0 | N/A |
| Gregory L. Verdine | Co-Founder | 0 | 1959 |
| John Knighton | Vice President & Chief Compliance Officer | 0 | 1978 |
| Steve Barbera | Vice President of Market Access | 0 | N/A |
| Elly Ryu | Corporation Controller & Principal Accounting Officer | 0 | 1981 |
| Erin Clark | Vice President of Corporation Strategy & Investor Relations | 0 | N/A |
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
